BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Ets-1 enhances tumor migration through regulation of CCR7 expression
Li-Wen Fang2, Ying-Hsien Kao1,4, Ya-Ting Chuang3, Huey-Lan Huang5, Tzong-Shyuan Tai1,4,*
1Department of Medical Research, E-Da Hospital,
2Department of Nutrition, I-Shou University,
3Department of Medical Research, National Taiwan University Hospital,
4I-Shou University,
5Department of Bioscience Technology, Chang Jung Christian University
Ets-1 is a prototype of the ETS protein family, the members of which contain a unique ETS domain. Ets-1 is associated with cancer progression and metastasis in many types of cancer. In many studies, the elevated expression of Ets-1 in cancer biopsies has been linked to poor survival. CCR7 is a chemokine that binds to the specific ligand CCL21/CCL19. CCR7 expression is associated with tumor metastasis and infiltration into lymph nodes. In this study, we tested whether Ets-1 could regulate CCR7 expression and enhance tumor metastasis. Our data show that CCR7 expression is downregulated in Ets-1-deficient T cells upon T-cell stimulation. The overexpression of Ets-1 increases CCR7 expression in breast cancer cell lines. In contrast, the knockdown of Ets-1 reduces CCR7 expression. Ets-1 directly binds to the CCR7 promoter and mediates CCR7 expression in luciferase reporter assays and chromatin immunoprecipitation assays. The transactivation activity of Ets-1 is independent of the Pointed domain of Ets-1. Ets-1 also enhances the NF-B and CBP transactivation of the CCR7 promoter. Finally, we show that Ets-1 can modulate cancer cell transmigration by altering CCR7 expression in a transwell assay and wound healing assay. Taken together, our data suggest that Ets-1 enhances CCR7 expression and contributes to tumor cell migration.
Abstract, Accepted Manuscript(in press) [Submitted on October 2, 2018, Accepted on December 23, 2018]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd